Progress on EGFR-TKI in treatment of non-small cell lung cancer with S768I mutation / 中国肿瘤临床

Lung cancer is one of the malignant tumors with high mortality rates. In recent years, considerable progress on the treat-ment of non-small cell lung cancer has been achieved. Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) improves the median progression free survival of patients with sensitive mutations to 27.7 months. However, the therapeutic effect of EGFR-TKI on uncommon mutations remains unknown. S768I mutation is an insensitive mutation in the EGFR20 exon, and its incidence rate rang-es from 1％to 2％. In this review, the effect of different generation EGFR-TKI on single or complex S768I mutation during treatment is discussed.